Strontium ranelate inhibits urinary excretion of CTX-II, a marker of cartilage degradation, in postmenopausal women

in Osteoporosis International (2005, March), 16(suppl.3), 60

Strontium Ranelate normalizes bone mineral density in osteopenic patients

in Osteoporosis International (2006, March), 17(Suppl.1), 63

Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies

in Osteoporosis International (2003), 14(Suppl. 3), 56-65

The aim of the PREVOS study (PREVention Of early postmenopausal bone loss by Strontium ranelate) and the STRATOS study (STRontium Administration for Treatment of OSteoporosis) was to determine the minimum ... [more ▼]

The aim of the PREVOS study (PREVention Of early postmenopausal bone loss by Strontium ranelate) and the STRATOS study (STRontium Administration for Treatment of OSteoporosis) was to determine the minimum dose at which strontium ranelate (SR) is effective in, respectively, the prevention of bone loss in early postmenopausal nonosteoporotic women and the treatment of postmenopausal vertebral osteoporosis. Both studies were randomized, double-blind, placebo-controlled, dose-finding studies in parallel groups and lasted 2 years. In the PREVOS study, 160 early postmenopausal women were randomized to receive placebo, SR 125 mg/day, 500 mg/day or 1 g/day. In the STRATOS study, 353 osteoporotic postmenopausal women with at least one previous vertebral fracture and a lumbar T-score < -2.4 were randomized to receive placebo, SR 500 mg/day, 1 g/day or 2 g/day. In both studies, the primary efficacy parameter was lumbar bone mineral density (BMD) measured by dual-energy X-ray absorptiometry. Secondary efficacy criteria included incidence of new vertebral deformities (in the STRATOS study only) and biochemical markers of bone metabolism. In the PREVOS study, the increase in lumbar BMD from baseline in the 1 g/day group (+ 5.53%) was significantly different from the decrease in the placebo group (p < 0.001). In the STRATOS study, the annual increase in lumbar BMD in the 2 g/day group (+7.3% per year) was significantly higher than in the placebo group (p<0.001). There was a significant reduction in the number of patients experiencing new vertebral deformities in the second year of treatment in the 2 g/day group (relative risk: 0.56; 95% confidence interval: 0.35, 0.89). In both studies, there was a significant increase in the bone formation marker (bone alkaline phosphatase) in the higher-dose group. Urinary excretion of the marker of bone resorption (cross-linked N-telopeptide) was lower with SR than with placebo in the STRATOS study. SR was very well tolerated in both studies. The minimum dose at which SR is effective in preventing bone loss in early postmenopausal nonosteoporotic women and in the treatment of postmenopausal osteoporosis is 1 g/day and 2 g/day, respectively. [less ▲]

Strontium ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis

in Osteoporosis International (2012, March), 23(S2), 366-367

Strontium ranelate reduces the risk of fracture in elderly women with osteoporosis in the first year of treatment

in Osteoporosis International (2006, June), 17(Suppl.2), 85-86

Strontium ranelate reduces the risk of non vertebral fractures in women with postmenopausal osteoporosis

in Osteoporosis International (2003, November), 14(Suppl. 7), 51-52

Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with post-menopausal osteoporosis.

in Calcified Tissue International (2004), 74(S1), 37-38

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

in Journal of Bone and Mineral Research (2006), 21(7), 1113-1120

Introduction: About 25-30% of the population burden of all fragility fractures in the community arise from women >= 80 years of age, because this population is at high risk for all types of fracture ... [more ▼]

Introduction: About 25-30% of the population burden of all fragility fractures in the community arise from women >= 80 years of age, because this population is at high risk for all types of fracture, particularly nonvertebral fractures. Despite this, evidence that therapies reduce the risk of both vertebral and nonvertebral fractures in this group is lacking. The aim of this study was to determine whether strontium ranelate, an agent that reduces the risk of vertebral and nonvertebral fractures in postmenopausal women > 50 years of age, also reduces fractures in the elderly. Materials and Methods: An analysis based on preplanned pooling of data from two international, phase 111, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis, Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]) included 1488 women between 80 and 100 years of age followed for 3 years. Yearly spinal X-rays were performed in 895 patients. Only radiographically confirmed nonvertebral fractures were included. Results: Baseline characteristics did not differ in placebo and treatment arms. In the intent-to-treat analysis, the risk of vertebral, nonvertebral, and clinical (symptomatic vertebral and nonvertebral) fractures was reduced within I year by 59% (p = 0.002), 41% (p = 0.027), and 37% (p = 0.012), respectively. At the end of 3 years, vertebral, nonvertebral, and clinical fracture risks were reduced by 32% (p = 0.013), 31% (p = 0.011), and 22% (p = 0.040), respectively. The medication was well tolerated, and the safety profile was similar to that in younger patients. Conclusions: Treatment with strontium ranelate safely reduces the risk of vertebral and nonvertebral fractures in women with osteoporosis >= 80 years of age. Even in the oldest old, it is not too late to reduce fracture risk. [less ▲]

Strontium ranelate reduces the risk of vertebral fracture in patients with osteopenia

in Osteoporosis International (2006, March), 17(Suppl.1), 50

Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fracture status

in BONE (2005), 36(S2), 403